WO2019125058A1 - Composition comprising a horse chestnut extract - Google Patents
Composition comprising a horse chestnut extract Download PDFInfo
- Publication number
- WO2019125058A1 WO2019125058A1 PCT/KR2018/016486 KR2018016486W WO2019125058A1 WO 2019125058 A1 WO2019125058 A1 WO 2019125058A1 KR 2018016486 W KR2018016486 W KR 2018016486W WO 2019125058 A1 WO2019125058 A1 WO 2019125058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- horse chestnut
- chestnut extract
- implantitis
- present
- peri
- Prior art date
Links
- 235000020721 horse chestnut extract Nutrition 0.000 title claims abstract description 155
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 208000006389 Peri-Implantitis Diseases 0.000 claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 41
- 235000013305 food Nutrition 0.000 claims abstract description 22
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 claims description 53
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 claims description 53
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 claims description 53
- SOSLMHZOJATCCP-AEIZVZFYSA-N afzelin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O SOSLMHZOJATCCP-AEIZVZFYSA-N 0.000 claims description 53
- SOSLMHZOJATCCP-PADPQNGGSA-N afzelin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O SOSLMHZOJATCCP-PADPQNGGSA-N 0.000 claims description 53
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 claims description 53
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 claims description 53
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 claims description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- 235000010181 horse chestnut Nutrition 0.000 claims description 22
- 241000157282 Aesculus Species 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 125000003158 alcohol group Chemical group 0.000 claims 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 34
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 34
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 23
- 239000000306 component Substances 0.000 description 23
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 17
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 17
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 17
- 235000008777 kaempferol Nutrition 0.000 description 17
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 17
- 235000005875 quercetin Nutrition 0.000 description 17
- 229960001285 quercetin Drugs 0.000 description 17
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- -1 anhydrous aescin Chemical class 0.000 description 9
- 239000011534 wash buffer Substances 0.000 description 9
- 239000007943 implant Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 239000012930 cell culture fluid Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000000770 proinflammatory effect Effects 0.000 description 7
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 6
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000157280 Aesculus hippocastanum Species 0.000 description 5
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 5
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010874 in vitro model Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001119624 Aesculus chinensis Species 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 241001646648 Aesculus turbinata Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 101000605126 Mus musculus Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000005550 inflammation mediator Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940056211 paraffin Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001143502 Hippocastanaceae Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940045809 horse chestnut seed Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
Definitions
- the present invention relates to a pharmaceutical composition for preventing or treating peri-implantitis, containing a horse chestnut extract as an effective component, and a food composition for preventing or reducing peri-implantitis, containing a horse chestnut extract as an effective component.
- peri-implantitis is a disease that appears around the implant rather than a natural tooth, and thus requires most attentions after a procedure of the implant. It is reported that peri-implantitis occurs from 60% or more of the implants ever performed. In particular, the implant has a problem in that it does not have nerves distributed therein, unlike the natural tooth, and thus an outbreak of peri-implantitis may not be well recognized in an early stage of development, but recognized only after serious worsening of symptoms. However, if peri-implantitis leaves alone without any treatment in its early stage of development, peri-implantitis may even cause an alveolar bone to collapse in a severe case. Thus, peri-implantitis requires a careful treatment, and a serious bone loss around the implant may go so far as to require a re-operation due to a failure of the implant.
- peri-implantitis progresses fast in comparison with other diseases developed in the natural tooth, and also tends to show a higher degree of severity.
- peri-implantitis have not effectively or fundamentally treated peri-implantitis, but have simply alleviated its symptoms only.
- peri-implantitis it has been difficult to treat peri-implantitis with a drug only, but other methods such as a surgical procedure, an operation or the like have been mainly used instead.
- the present invention provides a pharmaceutical composition for preventing or treating peri-implantitis, containing a horse chestnut extract as an effective component.
- the present invention provides the pharmaceutical composition for preventing or treating peri-implantitis, containing the horse chestnut extract as an effective component, in which the said horse chestnut extract contains quercitrin and afzelin.
- the present invention provides a method for preparing a horse chestnut extract, including: a first step of crushing a horse chestnut; and a second step of performing an extraction from the said crushed horse chestnut by means of an alcohol aqueous solution.
- the present invention provides a food composition for preventing or reducing peri-implantitis, containing a horse chestnut extract as an effective component.
- the present invention provides the food composition for preventing or reducing peri-implantitis, containing the horse chestnut extract as an effective component, in which the said horse chestnut extract contains quercitrin and afzelin.
- the present invention provides a pharmaceutical composition for preventing or treating peri-implantitis, containing a horse chestnut extract as an effective component.
- the present invention provides the pharmaceutical composition for preventing or treating peri-implantitis, containing the horse chestnut extract as an effective component, in which the said horse chestnut extract contains quercitrin and afzelin.
- the horse chestnut extract according to the present invention may prevent or treat peri-implantitis.
- Conventional drugs have done nothing more than alleviating only the accompanying symptoms of peri-implantitis, and have failed to fundamentally treat peri-implantitis, and thus have caused a situation, in which patients are subjected to a surgical operation as a last resort or receive the implant again.
- the horse chestnut extract according to the present invention achieves excellent effects of being able to alleviate symptoms of peri-implantitis and also being able to fundamentally prevent or treat peri-implantitis.
- the horse chestnut extract according to the present invention may prevent or treat peri-implantitis by effectively inhibiting an activity of VEGF.
- an "effective component” means a component that may show an intended activity when used alone, or may show the activity when used in combination with a carrier without an activity.
- the said "prevention” means all the acts that inhibit or delay an outbreak of disease by means of administration of the said pharmaceutical composition containing the horse chestnut extract.
- the said “treatment” includes an act, by which a disease gets better or takes a favorable turn by means of administration of the said pharmaceutical composition containing the horse chestnut extract, and an act, by which a progression of disease is inhibited or a speed of such progression is delayed.
- the "horse chestnut” belongs to a horse chestnut family (Hippocastanaceae), and is also called conker tree as well as marronier in France.
- the horse chestnut extract may be obtained from a leaf or seed ( Aesculus chinensis ), particularly from the leaf.
- the horse chestnut extract according to the present invention may be also used in such a way that a horse chestnut leaf currently available or a leaf harvested from spring through to autumn is dried in the shade.
- the said horse chestnut extract may be a dry extract of the horse chestnut, which is prepared from a horse chestnut seed, and the one that contains triterpene glycosides, i.e. anhydrous aescin, in an amount of 10 wt% or more, may be used as a reference standard. More preferably, an extract of the horse chestnut leaf may be used.
- the said horse chestnut may be a Japanese horse chestnut ( Aesculus turbinata BLUME), Chinese horse chestnuts ( Aesculus chinensis Bge and Aesculus wilculus Rehd), an European horse chestnut ( Aesculus hippocastanum L.) and the like, particularly the European horse chestnut ( Aesculus hippocastanum L.), but is not limited thereto.
- the said horse chestnut extract contains quercitrin and afzelin.
- quercitrin may be represented by a following Formula 1:
- afzelin may be represented by a following Formula 2:
- the said horse chestnut extract may contain the said quercitrin and the said afzelin at a weight ratio of about 2:1 to 30:1.
- the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 2:1 to 20:1.
- the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 3:1 to 10:1. More particularly, the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 3:1 to 6:1.
- the said horse chestnut extract may be an alcohol aqueous solution extract.
- the said alcohol may be an alcohol having 1 to 4 carbon atoms, and may be methanol, ethanol or a mixture thereof.
- the horse chestnut extract (ALH-L1005) according to the present invention may be about 20 to 30% (w/v) ethanol aqueous solution extract, particularly about 20 to 25% (w/v) ethanol aqueous solution extract, and more particularly about 25% (w/v) ethanol aqueous solution extract.
- the said horse chestnut extract may contain the said quercitrin in an amount of about 0.5 wt% to 7 wt%, based on the total weight of the horse chestnut extract.
- the said horse chestnut extract may contain the said afzelin in an amount of about 0.02 wt% to 2.5 wt%, particularly in an amount of about 0.1 wt% to 1.5 wt%, based on the total weight of the horse chestnut extract.
- the inventive horse chestnut extract may have an excellent effect of preventing or treating peri-implantitis.
- the contents of quercitrin and afzelin in the said horse chestnut extract may be subject to change depending on areas, years and harvest times within a range, in which such effect is maintained.
- the contents of quercitrin and afzelin in the horse chestnut extract may be measured by quantifying the contents of the said quercitrin and afzelin contained in the extract.
- the quercitrin and afzelin contained in the horse chestnut extract according to the present invention may be converted into other substances during a quantification process.
- the quantification process needs to be strictly adjusted.
- the contents of quercitrin and afzelin in the said horse chestnut extract may be measured by converting the said compounds into quercetin represented by a following Formula 3 and kaempferol represented by a following Formula 4, respectively.
- the contents of quercitrin and afzelin in the said horse chestnut extract may be measured by converting the said substances in the extract into quercetin and kaempferol respectively without a separation between quercitrin and afzelin in the said horse chestnut extract, and thus quantifying such quercetin and kaempferol.
- the quercitrin and afzelin in the said extract may be converted into quercetin and kaempferol.
- Quercetin represented by the Formula 3 above and kaempferol represented by the Formula 4 above are relatively more stable than quercitrin and afzelin respectively and are not converted well during quantification, and thus quantification thereof is relatively easy and accurate quantification is also possible.
- the contents of quercitrin and afzelin in the horse chestnut extract may be consistently and accurately measured.
- quercetin and kaempferol are not contained in the said horse chestnut extract, the contents of quercitrin and afzelin contained in the horse chestnut extract may be accurately identified by converting quercitrin and afzelin into quercetin and kaempferol respectively, and then measuring the contents of such quercetin and kaempferol.
- an index substance of the said horse chestnut extract may be quercitrin and afzelin.
- the quercitrin and afzelin in the said horse chestnut extract may be measured by converting the said substances into quercetin and kaempferol respectively, and then quantifying such quercetin and kaempferol.
- the said horse chestnut extract may be specified by means of the contents of the said quercetin and kaempferol.
- an index substance of the said horse chestnut extract may be quercetin and kaempferol.
- the said horse chestnut extract may be specified by means of the contents of quercetin and kaempferol, not by measuring the contents of quercitrin and afzelin contained in the said horse chestnut extract, but by converting the quercitrin and afzelin in the said horse chestnut extract into quercetin and kaempferol, and then by quantifying the said quercetin and kaempferol.
- a process for converting quercitrin represented by the Formula 1 above into quercetin represented by the Formula 3 above may be performed by means of various methods known in the field, particularly an acid hydrolysis method.
- the quercitrin in the horse chestnut extract may be converted into quercetin by dissolving the horse chestnut extract in an organic solvent, and then treating with strong acid such as hydrochloric acid.
- a process for converting afzelin represented by the Formula 2 above into kaempferol represented by the Formula 4 above may be performed by means of various methods known in the field, particularly an acid hydrolysis method.
- the afzelin in the horse chestnut extract may be converted into kaempferol by dissolving the horse chestnut extract in an organic solvent, and then treating with strong acid such as hydrochloric acid.
- the said pharmaceutical composition may contain the said horse chestnut extract in an amount of about 0.005 wt% to 70 wt%, particularly the said horse chestnut extract in an amount of about 0.01 wt% to 50 wt%, more particularly the said horse chestnut extract in an amount of about 0.01 wt% to 20 wt%, and even more particularly the said horse chestnut extract in an amount of about 0.01 wt% to 10 wt%, based on the total weight of the said pharmaceutical composition.
- the said pharmaceutical composition containing the horse chestnut extract may further contain a pharmaceutically acceptable additive.
- the said additive may be a pharmaceutically acceptable carrier, excipient, binder, glidant, filler, extender, humectant, disintegrant, surfactant, diluent, lubricant, preservative, etc., but is not limited thereto.
- the pharmaceutically acceptable additive may be starch, gelatinized starch, microcrystalline cellulose, calcium carbonate, copovidone, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, sucrose, taffy, gum Arabic, pregelatinized starch, maize starch, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, gelatin, opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, magnesium, dextrose, sorbitol, talc, propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethyl oleate, liquid paraffin, Ringer's solution, wax, paraffin, tragacanth, silicon, bentonite, silica, talc, zinc oxide, chlorofluoro hydrocarbon, propane-
- the said pharmaceutical composition containing the horse chestnut extract may be appropriately formulated into an oral or parenteral dosage form for human or veterinary purposes.
- the appropriate dosage form may be the one disclosed in a document (e.g. Remington's Pharmaceutical Science (latest version), Mack Publishing Company, Easton PA).
- the said pharmaceutical composition containing the horse chestnut extract may be formed in such a way that the horse chestnut extract is filled without an additive like an excipient of a capsule, or evenly and sufficiently contacted by an atomized solid carrier or a liquid carrier, or both thereof, and then a resulting product may be molded into a preferable preparation, if necessary.
- the said horse chestnut extract may be formulated into an ointment dosage form along with an ointment base, etc., or formulated into a spray dosage form along with a polymer, etc.
- a solid preparation for oral administration may include a tablet, pill, powder, granule, capsule and the like, particularly the tablet or capsule.
- Such solid preparation may be prepared by mixing at least one or more additives, for example, starch, calcium carbonate, sucrose, lactose, gelatin, magnesium, stearate, talc, etc. in the pharmaceutical composition containing the horse chestnut extract.
- a liquid preparation for oral administration includes a suspending agent, liquid for internal use, emulsion, syrup and the like, and may include various additives, for example, a humectant, sweetening agent, flavoring agent, preservative and the like in addition to water and liquid paraffin, which are frequently used simple diluents.
- a preparation for parental administration may include a sterilized aqueous solution, non-aqueous solvent, suspending agent, emulsion, freeze-dried preparation, suppository, cream for local application, ointment, gel, spray, patch or the like.
- non-aqueous solvent and the suspending agent propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethyl oleate, etc. may be used.
- a dissolvent, concentrate, gelant, softener, antioxidant, stabilizer, foaming agent, surfactant, emulsifier, etc. may be used, particularly wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide, chlorofluoro hydrocarbon, propane-butane, dimethyl ether or the like may be used.
- the said pharmaceutical composition containing the horse chestnut extract may further contain a component, which does not increase a drug efficacy, but is conventionally used in the pharmaceutical composition to improve smell, taste, visual impression, etc.
- the term "administration" means that the said pharmaceutical composition containing the horse chestnut extract is introduced into an individual by means of an appropriate method.
- the pharmaceutical composition containing the horse chestnut extract may reach a target tissue via an administration route, such composition may be orally or parentally administered through a certain general route, particularly orally or locally administered, and more particularly orally administered in a form of tablet or capsule or locally administered in a form of spray so as to be easily attached to a certain tissue.
- the said pharmaceutical composition containing the horse chestnut extract may be orally or parentally administered depending on an intended method.
- the said pharmaceutical composition containing the horse chestnut extract may be orally administered by means of a tablet, capsule, soft capsule, infusion solution, granule, pill, etc., or may be parentally administered in an injectable form (solution, suspension or emulsion).
- the said pharmaceutical composition containing the horse chestnut extract may be orally administered in a form of tablet or capsule.
- the said pharmaceutical composition containing the horse chestnut extract may be administered alone to prevent or treat peri-implantitis.
- the said pharmaceutical composition containing the horse chestnut extract may be administered in combination with a known drug to treat peri-implantitis.
- the said pharmaceutical composition containing the horse chestnut extract may be administered sequentially or simultaneously with another drug. If being sequentially administered, such composition may be administered before administration of another known drug or after administration of another known drug.
- the said pharmaceutical composition containing the horse chestnut extract may be used in combination with a known surgical procedure or operation for treating peri-implantitis.
- the said pharmaceutical composition containing the horse chestnut extract may be administered before the surgical procedure or operation, administered along with the surgical procedure or operation, or administered after the surgical operation or treatment.
- the said pharmaceutical composition containing the horse chestnut extract according to the present invention may prevent or treat peri-implantitis by being administered into an individual.
- the "individual” means a mammal such as a horse, sheep, pig, goat, dog, etc., including a human, particularly means the human, who has peri-implantitis and whose peri-implantitis may be prevented or treated by administering the said pharmaceutical composition containing the horse chestnut extract according to the present invention thereinto.
- the said pharmaceutical composition containing the horse chestnut extract according to the present invention may be administered by a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount enough to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and a level of effective dosage may be determined according to factors including a patient's weight, gender, age, health condition, severity, activity of a drug, sensitivity to a drug, an administration time, an administration route and excretion rate, a treatment period and a concurrently used drug, as well as other factors well known in a medical field.
- a daily dosage of the said horse chestnut extract may amount to about 0.05 mg/kg to 200 mg/kg, particularly about 0.1 mg/kg to 100 mg/kg, and the said dosage may be appropriately adjusted depending on a patient's age, weight and degree of disease.
- a content of the said horse chestnut extract per unit dosage form may amount to about 1 mg to 2 g, particularly about 5 mg to 1 g, more particularly about 10 mg to 1 g, and even more particularly about 100 mg to 800 mg.
- the said horse chestnut extract may be administered once a day or several times a day, particularly twice a day to three times a day, which may be appropriately adjusted depending on a patient's age, weight and degree of disease.
- the present invention provides a food composition for preventing or reducing peri-implantitis, containing the horse chestnut extract as an effective component.
- the present invention provides the food composition for preventing or reducing peri-implantitis, containing the horse chestnut extract as an effective component, in which the horse chestnut extract contains quercitrin and afzelin.
- the said "food composition” means a food prepared and processed by using a raw material or component, which has a functionality useful to the human body.
- the said horse chestnut extract contained in the said food composition containing the said horse chestnut extract may contain the said quercitrin and the said afzelin at a weight ratio of about 2:1 to 30:1.
- the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 2:1 to 20:1.
- the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 3:1 to 10:1. More particularly, the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 3:1 to 6:1.
- the matters mentioned in the foregoing pharmaceutical composition may be equally applied to the said horse chestnut extract, if not contradictory to each other.
- the said food composition may be also taken in as it is or along with another food or food component, and may be appropriately taken in according to a conventional method.
- a type of the said food composition is not particularly limited.
- the said food composition containing the horse chestnut extract as an effective component there are a variety of soups, beverages, teas, health drinks, alcoholic beverages, vitamin complexes and the like, and all the health foods in a conventional sense may be included.
- the composition containing the horse chestnut extract according to the present invention may contain various nutritional supplements, vitamin, electrolyte, flavoring agent, coloring agent, pectic acid and salts thereof, alginic acid and salts thereof, organic acid, protective colloidal thickener, pH adjusting agent, stabilizer, preservative, glycerin, alcohol, carbonator used in carbonated beverage, etc.
- the food composition according to the present invention may contain natural fruit juice and pulp for preparing fruit juice beverage and vegetable based beverage. Such components may be used independently or in combination.
- the present invention provides a method for preparing a horse chestnut extract, including: a first step of crushing a horse chestnut; and a second step of putting the crushed horse chestnut into an alcohol aqueous solution and performing an extraction therefrom.
- the said alcohol may be an alcohol having 1 to 4 carbon atoms, particularly methanol, ethanol or a mixture thereof, and more particularly ethanol.
- the extraction in the said second step may be performed at about 40°C to 90°C, particularly at about 45°C to 85°C.
- the extraction in the said second step may be a known extraction method, for example, an ultrasonic extraction method or a reflux extraction method, but is not limited thereto.
- the said method may further include a step of drying the horse chestnut, before crushing the said horse chestnut.
- the said method may further include a third step of filtering and concentrating an extract obtained in the said second step.
- the said method may further include a fourth step of drying a concentrate obtained in the third step and preparing a resulting dry product into powder.
- the said method may further include a step of performing a supercritical treatment for a crushed horse chestnut between the said first step and the said second step.
- the said supercritical treatment may use carbon dioxide as fluid, in which a treatment temperature, pressure and treatment time may be appropriately adjusted by those skilled in the art.
- the said horse chestnut extract contains quercitrin and afzelin.
- the said horse chestnut extract may contain the said quercitrin in an amount of about 0.5 wt% to 7 wt%, based on the total weight of the horse chestnut extract.
- the said horse chestnut extract may contain the said afzelin in an amount of about 0.02 wt% to 2.5 wt%, particularly in an amount of about 0.1 wt% to 1.5 wt%, based on the total weight of the horse chestnut extract.
- the present invention may provide a pharmaceutical composition containing the horse chestnut extract prepared by means of the said preparation method as an effective component.
- the said pharmaceutical composition may be the same as described in the pharmaceutical composition described above.
- the present invention may provide a food composition containing the horse chestnut extract prepared by means of the said preparation method as an effective component.
- the said food composition may be the same as described in the food composition described above.
- the present invention provides a method for preventing or treating peri-implantitis by administering the pharmaceutical composition containing the horse chestnut extract into an individual.
- the said horse chestnut extract contains quercitrin and afzelin.
- the present invention provides a use of the horse chestnut extract for preventing or treating peri-implantitis.
- the said horse chestnut extract contains quercitrin and afzelin.
- the present invention provides a use of the horse chestnut extract for preparing a drug, which is used to prevent or treat peri-implantitis.
- the said horse chestnut extract contains quercitrin and afzelin.
- Matters mentioned in the pharmaceutical composition according to the present invention may be also equally applied to a method for manufacturing an extract, a food composition, a treatment method and a use, if not contradictory to each other.
- a pharmaceutical composition containing a horse chestnut extract according to the present invention as an effective component has an effect of preventing or treating peri-implantitis.
- FIG. 1 graphically illustrates an effect of a horse chestnut extract on inhibiting VEGF.
- FIG. 2 graphically illustrates a result of NO production.
- a vertical axis shows an absorbance.
- FIG. 3 graphically illustrates a result of a cytotoxicity assay experiment.
- FIG. 4 graphically illustrates an expression level of intereukin-6 measured by means of an ELISA.
- FIG. 5 graphically illustrates an expression level of cyclooxygenase measured by means of an ELISA.
- FIG. 6 graphically illustrates an expression level of prostaglandin measured by means of an ELISA.
- FIG. 7 graphically illustrates an HPLC result of the horse chestnut extract.
- FIG. 8 graphically illustrates an HPLC result of quercitrin and afzelin reference standards.
- the leaves of a horse chestnut ( Aesculus hippocastanum L.), collected at Doma-dong and Jeonmin-dong, Daejeon Metropolitan City, South Korea, were dried at room temperature in the shade, and then crushed. An extraction from about 30 g of resulting crushed leaves was performed by means of about 600 ml of about 25% (w/v) ethanol at about 80°C for two hours, and a resulting extract was filtered. A resulting filtrate was concentrated, and thus a resulting extract of the horse chestnut leaves was obtained by about 3.4 g.
- the horse chestnut extract prepared in Example 1 was designated as ALH-L1005.
- a 96-well plate (Corning, USA) was inoculated with a HUVEC (Human Umbilical Vein Endothelial Cells) at a ratio of 3 x 10 4 cells/well, in which a medium was an EBM-2 + 2% FBS medium.
- HUVEC Human Umbilical Vein Endothelial Cells
- the horse chestnut extract according to the present invention may effectively treat peri-implantitis by effectively inhibiting the VEGF.
- a macrophage in an inflammatory response produces a pro-inflammatory cytokine like an inflammation mediator such as TNF- ⁇ , intereukin-6 (IL-6) and IL-1*?*, then synthesizes an inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and then produces NO and prostaglandin E2 (PGE2).
- a pro-inflammatory cytokine like an inflammation mediator such as TNF- ⁇ , intereukin-6 (IL-6) and IL-1*?*, then synthesizes an inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and then produces NO and prostaglandin E2 (PGE2).
- iNOS inducible nitric oxide synthase
- COX-2 cyclooxygenase-2
- PGE2 prostaglandin E2
- an anti-inflammatory effect may be identified by identifying that NO produced from the inflammatory response is inhibited and production of the pro-inflammatory cytokine is inhibited.
- a concentration of nitric oxide (NO) in a culture fluid was measured by means of a Griess response.
- RAW 264.7 cells were adjusted at a ratio of 1 x 10 6 cells/mL, then inoculated into a 24-well plate, and then pre-cultured in a about 5% CO 2 incubator at about 37°C for two hours. After that, the cells were treated with the horse chestnut extract obtained in Example 1 at ratios of 0, 25, 50, 75 and 100 ug/mL, then stimulated by means of an LPS of 1 ug/mL in one hour later, and then mainly cultured for about 24 hours.
- NO nitric oxide
- a resulting supernatant and a Griess reagent (1% sulfanilamide + 0.1% naphthylendiamine dihydrochloride, 1:1) were reacted to each other at a ratio of 1:1 at room temperature for about 10 minutes, and then an observance thereof was measured at about 540 nm by means of a microplate reader.
- a murine macrophage cell line i.e. RAW264.7 cells were divided into a 96-well plate (Corning, USA) so that the number of cells may amount to 1 x 10 4 cells/well, and then cultured in a CO 2 incubator (37°C, 5% CO 2 ) for two hours. After cultivation, the resulting cells were treated with the horse chestnut extract according to the present invention at each concentration of 0, 25, 50, 75 and 100 ug/mL, and cultured at about 37°C for one hour. After cultivation, the resulting cells were treated with lipopolysaccharides (LPS) at a concentration of 1 ug/mL, and cultured at about 37°C for about 24 hours.
- LPS lipopolysaccharides
- the resulting cells were treated with an XTT reagent at a ratio of about 50 ul per well, then reacted for four hours, then an observance change thereof was measured at about 490 nm by means of the ELISA reader (Molecular Devices, USA), and then a cell viability thereof was indicated as a percentage.
- IL-6 intereukin-6 secretion from RAW 264.7 cells in a cell culture fluid was measured by using an ELISA kit (Mouse ELISA set, R&D Systems Inc.). To obtain the cell culture fluid, the RAW 264.7 cells were adjusted at a ratio of 5 x 10 6 cells/mL, then inoculated into a 24-well plate, then was pre-cultured for two hours, and then treated with the inventive horse chestnut extract at each concentration of 0, 25, 50, 75 and 100 ug/mL as well as an LPS of 1 ug/mL. After that, a main cultivation was performed for about 24 hours, and thus supernatant was obtained through centrifugation.
- ELISA kit Manton ELISA set, R&D Systems Inc.
- an anti-mouse IL-6 was divided into a microplate as a capture antibody, and then coated overnight at room temperature. After that, the microplate was washed with a wash buffer (#WA126, R&D Systems Inc.), then blocked by means of a reagent diluent (#DY995, R&D Systems Inc.), then washed with the wash buffer, and then a supernatant of cell culture was divided into each microplate well and reacted at room temperature for two hours.
- a wash buffer #WA126, R&D Systems Inc.
- a reagent diluent #DY995, R&D Systems Inc.
- the microplate was washed with the wash buffer, and then a diluted biotinylated anti-mouse IL-6 detection antibody and streptavidin-horseradish peroxidase conjugate were divided thereinto and reacted at room temperature for about 20 minutes.
- the microplate was washed with the wash buffer again, then a substrate solution (#DY999, R&D Systems Inc.) was added thereinto, and then dark-reacted at room temperature for about 20 minutes.
- the reaction was ended by means of a stop solution (#DY994, R&D Systems Inc.), and then an observance thereof was measured at about 450 nm by means of a microplate reader.
- the horse chestnut extract according to the present invention reduced an expression level of intereukin-6, i.e. the pro-inflammatory cytokine at concentrations of 25, 50, 75 and 100 ug/mL.
- the horse chestnut extract according to the present invention inhibited an NO production, had no cytotoxicity, and reduced an expression level of intereukin-6, i.e. the pro-inflammatory cytokine. From the results above, it may be identified that the horse chestnut extract according to the present invention showed an anti-inflammatory action by reducing the NO production with regard to Raw264.7 of macrophage, in which inflammation was induced by means of lipopolysaccharide (LPS), as well as an expression level of interleukin-6, i.e. an intracellular pro-inflammatory cytokine.
- LPS lipopolysaccharide
- Example 2-4 Inhibition of cyclooxygenase (COX-2) in an in-vitro model of peri-implantitis
- cyclooxygenase (COX-2) secretion from MG63 cells in a cell culture fluid was measured by using the ELISA kit (R&D Systems Inc.). To obtain the cell culture fluid, the MG63 cells were adjusted at a ratio of 1 X 10 6 cells/mL, then inoculated into a 60 mm culture plate, then pre-cultured for two hours, and then treated with the inventive horse chestnut extract at each concentration of 0, 25, 50, 75 and 100ug/mL as well as 10 ug/mL of LPS.
- the medium was discarded after a main culture for 48 hours, then the resulting cells were washed twice with PBS, then proteins were isolated therefrom by using a lysis buffer, and then used for the ELISA.
- anti-human/mouse COX-2 was divided into a microplate as a capture antibody and then coated overnight at room temperature. After that, the microplate was washed with a wash buffer, then blocked by means of a block buffer, then washed again with the wash buffer, after which isolated cell proteins were divided into each microplate well, and then subjected to reaction at room temperature for two hours.
- the microplate was washed with the wash buffer, after which diluted biotinylated anti-human/mouse COX-2 detection antibody and streptavidin-horseradish peroxidase conjugate were divided thereinto, and then subjected to reaction at room temperature for 20 minutes. After that, the microplate was washed with the wash buffer, after which a substrate solution was added thereinto, and then subjected to a dark reaction at room temperature for 20 minutes. The reaction was ended by mean of a stop solution, and then an absorbance thereof was measured at 450 nm by means of a microplate reader.
- the horse chestnut extract according to the present invention decreases an expression level of cyclooxygenase (COX-2) in a cell experiment using MG63, i.e. an in vitro model of peri-implantitis. From the results above, it might be identified that the horse chestnut extract according to the present invention achieves an effect on peri-implantitis by decreasing the expression level of cyclooxygenase (COX-2) with regard to MG63, in which an inflammation is induced by means of lipopolysaccharide (LPS), and thus showing an anti-inflammatory action.
- COX-2 cyclooxygenase
- Example 2-5 Inhibition of prostaglandin (PGE2) in the in vitro model of peri-implantitis
- PGE2 prostaglandin secretion from MG63 cells in a cell culture fluid was measured by using the ELISA kit (R&D Systems Inc.). To obtain the cell culture fluid, the MG63 cells were adjusted at a ratio of 1 X 10 6 cells/mL, then inoculated into a 60 mm culture plate, then pre-cultured for two hours, and then treated with the inventive horse chestnut extract at each concentration of 0, 25, 50, 75 and 100 ug/mL as well as 10 ug/mL of LPS.
- the cell culture fluid and a primary antibody solution (anti-PGE2 mouse monoclonal antibody) were inserted into a microplate, then subjected to reaction at room temperature for one hour, after which PGE2 conjugate was added thereinto, and then further subjected to reaction (for competitive ELISA) for two hours. After that, the microplate was washed four times in total with the wash buffer, after which the substrate solution was added thereinto, and then subjected to the dark reaction at room temperature for 30 minutes. The reaction was ended by mean of the stop solution, and then an absorbance thereof was measured at 450 nm by means of the microplate reader.
- a primary antibody solution anti-PGE2 mouse monoclonal antibody
- the horse chestnut extract according to the present invention inhibits a production of prostaglandin (PGE2), i.e. an inflammation mediator in a cell experiment using MG63, i.e. an in vitro model of peri-implantitis.
- PGE2 prostaglandin
- MG63 a cell experiment using MG63
- LPS lipopolysaccharide
- ALH-L1005 i.e. the horse chestnut extract, contains quercitrin and afzelin was identified as follows.
- HPLC was equally performed for a quercitrin reference standard (Sigma-Aldrich) and an afzelin reference standard (Sigma-Aldrich). The results thereof are as shown in FIG. 8.
- the conditions for performing the HPLC are as follows:
- Mobile phase A 0.1% (w/v) Formic acid ⁇ Mobile phase B: Acetonitrile
- the horse chestnut extract of Preparation Example 1 contained quercitrin and afzelin.
- the quercitrin reference standard in the said FIG. 2 showed a peak at a position where a retention time (RT) value is about 15 minutes
- the afzelin reference standard showed a peak at a position where the RT value is about 18 minutes.
- the horse chestnut extract of the said FIG. 1 also showed a peak at the same RT value, and thus it was clearly identified that ALH-L1005, i.e. the horse chestnut extract, contained quercitrin and afzelin.
- a weight ratio of quercitrin and afzelin to ALH-L1005 which was measured from the HPLC above, corresponded to about 4:1 to 5:1.
- the said horse chestnut extract contained quercitrin in an amount of about 1.88 to 2.20 wt% based on the total weight of the horse chestnut, and contained afzelin in an amount of about 0.41 to 0.5 wt% based on the total weight of the horse chestnut.
Abstract
The present invention provides a pharmaceutical composition for preventing or treating peri-implantitis, containing a horse chestnut extract as an effective component, or a food composition for preventing or reducing peri-implantitis, containing a horse chestnut extract as an effective component.
Description
The present invention relates to a pharmaceutical composition for preventing or treating peri-implantitis, containing a horse chestnut extract as an effective component, and a food composition for preventing or reducing peri-implantitis, containing a horse chestnut extract as an effective component.
With a growing use of a dental implant, various diseases associated with the implant have occurred a lot.
Out of those diseases, peri-implantitis is a disease that appears around the implant rather than a natural tooth, and thus requires most attentions after a procedure of the implant. It is reported that peri-implantitis occurs from 60% or more of the implants ever performed. In particular, the implant has a problem in that it does not have nerves distributed therein, unlike the natural tooth, and thus an outbreak of peri-implantitis may not be well recognized in an early stage of development, but recognized only after serious worsening of symptoms. However, if peri-implantitis leaves alone without any treatment in its early stage of development, peri-implantitis may even cause an alveolar bone to collapse in a severe case. Thus, peri-implantitis requires a careful treatment, and a serious bone loss around the implant may go so far as to require a re-operation due to a failure of the implant.
Also, peri-implantitis progresses fast in comparison with other diseases developed in the natural tooth, and also tends to show a higher degree of severity.
However, the existing drugs used to prevent or treat peri-implantitis have not effectively or fundamentally treated peri-implantitis, but have simply alleviated its symptoms only. Thus, upon the occurrence of peri-implantitis, it has been difficult to treat peri-implantitis with a drug only, but other methods such as a surgical procedure, an operation or the like have been mainly used instead.
Thus, there is a need to develop a drug that may effectively prevent or treat peri-implantitis.
The present invention provides a pharmaceutical composition for preventing or treating peri-implantitis, containing a horse chestnut extract as an effective component.
The present invention provides the pharmaceutical composition for preventing or treating peri-implantitis, containing the horse chestnut extract as an effective component, in which the said horse chestnut extract contains quercitrin and afzelin.
Also, the present invention provides a method for preparing a horse chestnut extract, including: a first step of crushing a horse chestnut; and a second step of performing an extraction from the said crushed horse chestnut by means of an alcohol aqueous solution.
Further, the present invention provides a food composition for preventing or reducing peri-implantitis, containing a horse chestnut extract as an effective component.
Furthermore, the present invention provides the food composition for preventing or reducing peri-implantitis, containing the horse chestnut extract as an effective component, in which the said horse chestnut extract contains quercitrin and afzelin.
Hereinafter, the present invention will be described in more detail.
The present invention provides a pharmaceutical composition for preventing or treating peri-implantitis, containing a horse chestnut extract as an effective component.
The present invention provides the pharmaceutical composition for preventing or treating peri-implantitis, containing the horse chestnut extract as an effective component, in which the said horse chestnut extract contains quercitrin and afzelin.
The horse chestnut extract according to the present invention may prevent or treat peri-implantitis. Conventional drugs have done nothing more than alleviating only the accompanying symptoms of peri-implantitis, and have failed to fundamentally treat peri-implantitis, and thus have caused a situation, in which patients are subjected to a surgical operation as a last resort or receive the implant again. However, the horse chestnut extract according to the present invention achieves excellent effects of being able to alleviate symptoms of peri-implantitis and also being able to fundamentally prevent or treat peri-implantitis. For example, the horse chestnut extract according to the present invention may prevent or treat peri-implantitis by effectively inhibiting an activity of VEGF.
In the present specification, when any part is said to "include" a certain component, this means that the part may further include other components rather than excluding the other components, unless otherwise especially specified.
In the present specification, an "effective component" means a component that may show an intended activity when used alone, or may show the activity when used in combination with a carrier without an activity.
In the present specification, the said "prevention" means all the acts that inhibit or delay an outbreak of disease by means of administration of the said pharmaceutical composition containing the horse chestnut extract. Also, the said "treatment" includes an act, by which a disease gets better or takes a favorable turn by means of administration of the said pharmaceutical composition containing the horse chestnut extract, and an act, by which a progression of disease is inhibited or a speed of such progression is delayed.
In the present specification, the "horse chestnut" belongs to a horse chestnut family (Hippocastanaceae), and is also called conker tree as well as marronier in France.
According to the exemplary embodiments of the present invention, the horse chestnut extract may be obtained from a leaf or seed (
Aesculus chinensis), particularly from the leaf.
For example, the horse chestnut extract according to the present invention may be also used in such a way that a horse chestnut leaf currently available or a leaf harvested from spring through to autumn is dried in the shade. Or the said horse chestnut extract may be a dry extract of the horse chestnut, which is prepared from a horse chestnut seed, and the one that contains triterpene glycosides, i.e. anhydrous aescin, in an amount of 10 wt% or more, may be used as a reference standard. More preferably, an extract of the horse chestnut leaf may be used.
According to the exemplary embodiments of the present invention, the said horse chestnut may be a Japanese horse chestnut (
Aesculus turbinata BLUME), Chinese horse chestnuts (
Aesculus chinensis Bge and
Aesculus wilculus Rehd), an European horse chestnut (
Aesculus hippocastanum L.) and the like, particularly the European horse chestnut (
Aesculus hippocastanum L.), but is not limited thereto.
According to the present invention, the said horse chestnut extract contains quercitrin and afzelin.
In the horse chestnut extract according to the present invention, quercitrin may be represented by a following Formula 1:
[Formula 1]
In the horse chestnut extract according to the present invention, afzelin may be represented by a following Formula 2:
[Formula 2]
According to the exemplary embodiments of the present invention, the said horse chestnut extract may contain the said quercitrin and the said afzelin at a weight ratio of about 2:1 to 30:1. Particularly, the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 2:1 to 20:1. Also, the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 3:1 to 10:1. More particularly, the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 3:1 to 6:1.
According to the exemplary embodiments of the present invention, the said horse chestnut extract may be an alcohol aqueous solution extract.
The said alcohol may be an alcohol having 1 to 4 carbon atoms, and may be methanol, ethanol or a mixture thereof. For example, the horse chestnut extract (ALH-L1005) according to the present invention may be about 20 to 30% (w/v) ethanol aqueous solution extract, particularly about 20 to 25% (w/v) ethanol aqueous solution extract, and more particularly about 25% (w/v) ethanol aqueous solution extract.
According to the exemplary embodiments of the present invention, the said horse chestnut extract may contain the said quercitrin in an amount of about 0.5 wt% to 7 wt%, based on the total weight of the horse chestnut extract.
According to the exemplary embodiments of the present invention, the said horse chestnut extract may contain the said afzelin in an amount of about 0.02 wt% to 2.5 wt%, particularly in an amount of about 0.1 wt% to 1.5 wt%, based on the total weight of the horse chestnut extract.
If the horse chestnut extract according to the present invention contains the said quercitrin and the said afzelin in the said range of weight ratios, the inventive horse chestnut extract may have an excellent effect of preventing or treating peri-implantitis.
However, the contents of quercitrin and afzelin in the said horse chestnut extract may be subject to change depending on areas, years and harvest times within a range, in which such effect is maintained.
According to one exemplary embodiment of the present invention, the contents of quercitrin and afzelin in the horse chestnut extract may be measured by quantifying the contents of the said quercitrin and afzelin contained in the extract.
The quercitrin and afzelin contained in the horse chestnut extract according to the present invention may be converted into other substances during a quantification process. Thus, in order to accurately quantify the said components contained in the said horse chestnut extract, the quantification process needs to be strictly adjusted.
According to another exemplary embodiment of the present invention, the contents of quercitrin and afzelin in the said horse chestnut extract may be measured by converting the said compounds into quercetin represented by a following Formula 3 and kaempferol represented by a following Formula 4, respectively.
[Formula 3]
[Formula 4]
Particularly, the contents of quercitrin and afzelin in the said horse chestnut extract may be measured by converting the said substances in the extract into quercetin and kaempferol respectively without a separation between quercitrin and afzelin in the said horse chestnut extract, and thus quantifying such quercetin and kaempferol. For example, if the said horse chestnut extract is treated with hydrochloric acid, the quercitrin and afzelin in the said extract may be converted into quercetin and kaempferol.
Quercetin represented by the Formula 3 above and kaempferol represented by the Formula 4 above are relatively more stable than quercitrin and afzelin respectively and are not converted well during quantification, and thus quantification thereof is relatively easy and accurate quantification is also possible. In result, comparing with the case, in which the contents of quercitrin and afzelin in the horse chestnut extract are directly measured, the contents of the said substances in the horse chestnut extract may be consistently and accurately measured.
Also, because quercetin and kaempferol are not contained in the said horse chestnut extract, the contents of quercitrin and afzelin contained in the horse chestnut extract may be accurately identified by converting quercitrin and afzelin into quercetin and kaempferol respectively, and then measuring the contents of such quercetin and kaempferol.
According to one exemplary embodiment of the present invention, an index substance of the said horse chestnut extract may be quercitrin and afzelin. However, the quercitrin and afzelin in the said horse chestnut extract may be measured by converting the said substances into quercetin and kaempferol respectively, and then quantifying such quercetin and kaempferol. In this case, the said horse chestnut extract may be specified by means of the contents of the said quercetin and kaempferol.
According to another exemplary embodiment of the present invention, an index substance of the said horse chestnut extract may be quercetin and kaempferol. In this case, the said horse chestnut extract may be specified by means of the contents of quercetin and kaempferol, not by measuring the contents of quercitrin and afzelin contained in the said horse chestnut extract, but by converting the quercitrin and afzelin in the said horse chestnut extract into quercetin and kaempferol, and then by quantifying the said quercetin and kaempferol.
A process for converting quercitrin represented by the Formula 1 above into quercetin represented by the Formula 3 above may be performed by means of various methods known in the field, particularly an acid hydrolysis method. For example, the quercitrin in the horse chestnut extract may be converted into quercetin by dissolving the horse chestnut extract in an organic solvent, and then treating with strong acid such as hydrochloric acid.
A process for converting afzelin represented by the Formula 2 above into kaempferol represented by the Formula 4 above may be performed by means of various methods known in the field, particularly an acid hydrolysis method. For example, the afzelin in the horse chestnut extract may be converted into kaempferol by dissolving the horse chestnut extract in an organic solvent, and then treating with strong acid such as hydrochloric acid.
According to the exemplary embodiments of the present invention, the said pharmaceutical composition may contain the said horse chestnut extract in an amount of about 0.005 wt% to 70 wt%, particularly the said horse chestnut extract in an amount of about 0.01 wt% to 50 wt%, more particularly the said horse chestnut extract in an amount of about 0.01 wt% to 20 wt%, and even more particularly the said horse chestnut extract in an amount of about 0.01 wt% to 10 wt%, based on the total weight of the said pharmaceutical composition.
According to the exemplary embodiments of the present invention, the said pharmaceutical composition containing the horse chestnut extract may further contain a pharmaceutically acceptable additive.
The said additive may be a pharmaceutically acceptable carrier, excipient, binder, glidant, filler, extender, humectant, disintegrant, surfactant, diluent, lubricant, preservative, etc., but is not limited thereto. For example, the pharmaceutically acceptable additive may be starch, gelatinized starch, microcrystalline cellulose, calcium carbonate, copovidone, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, sucrose, taffy, gum Arabic, pregelatinized starch, maize starch, powdered cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, gelatin, opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, magnesium, dextrose, sorbitol, talc, propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethyl oleate, liquid paraffin, Ringer's solution, wax, paraffin, tragacanth, silicon, bentonite, silica, talc, zinc oxide, chlorofluoro hydrocarbon, propane-butane, dimethyl ether or the like, but is not limited thereto.
According to the exemplary embodiments of the present invention, the said pharmaceutical composition containing the horse chestnut extract may be appropriately formulated into an oral or parenteral dosage form for human or veterinary purposes. Particularly, the appropriate dosage form may be the one disclosed in a document (e.g. Remington's Pharmaceutical Science (latest version), Mack Publishing Company, Easton PA).
For example, the said pharmaceutical composition containing the horse chestnut extract may be formed in such a way that the horse chestnut extract is filled without an additive like an excipient of a capsule, or evenly and sufficiently contacted by an atomized solid carrier or a liquid carrier, or both thereof, and then a resulting product may be molded into a preferable preparation, if necessary. Or the said horse chestnut extract may be formulated into an ointment dosage form along with an ointment base, etc., or formulated into a spray dosage form along with a polymer, etc.
A solid preparation for oral administration may include a tablet, pill, powder, granule, capsule and the like, particularly the tablet or capsule. Such solid preparation may be prepared by mixing at least one or more additives, for example, starch, calcium carbonate, sucrose, lactose, gelatin, magnesium, stearate, talc, etc. in the pharmaceutical composition containing the horse chestnut extract.
A liquid preparation for oral administration includes a suspending agent, liquid for internal use, emulsion, syrup and the like, and may include various additives, for example, a humectant, sweetening agent, flavoring agent, preservative and the like in addition to water and liquid paraffin, which are frequently used simple diluents.
A preparation for parental administration may include a sterilized aqueous solution, non-aqueous solvent, suspending agent, emulsion, freeze-dried preparation, suppository, cream for local application, ointment, gel, spray, patch or the like.
As the non-aqueous solvent and the suspending agent above, propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethyl oleate, etc. may be used.
As a base of cream for local administration, ointment, gel, spray, patch or the like, a dissolvent, concentrate, gelant, softener, antioxidant, stabilizer, foaming agent, surfactant, emulsifier, etc. may be used, particularly wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide, chlorofluoro hydrocarbon, propane-butane, dimethyl ether or the like may be used.
According to the exemplary embodiments of the present invention, the said pharmaceutical composition containing the horse chestnut extract may further contain a component, which does not increase a drug efficacy, but is conventionally used in the pharmaceutical composition to improve smell, taste, visual impression, etc.
As used herein, the term "administration" means that the said pharmaceutical composition containing the horse chestnut extract is introduced into an individual by means of an appropriate method. As long as the pharmaceutical composition containing the horse chestnut extract may reach a target tissue via an administration route, such composition may be orally or parentally administered through a certain general route, particularly orally or locally administered, and more particularly orally administered in a form of tablet or capsule or locally administered in a form of spray so as to be easily attached to a certain tissue.
According to the exemplary embodiments of the present invention, the said pharmaceutical composition containing the horse chestnut extract may be orally or parentally administered depending on an intended method. Particularly, the said pharmaceutical composition containing the horse chestnut extract may be orally administered by means of a tablet, capsule, soft capsule, infusion solution, granule, pill, etc., or may be parentally administered in an injectable form (solution, suspension or emulsion). For example, the said pharmaceutical composition containing the horse chestnut extract may be orally administered in a form of tablet or capsule.
According to one exemplary embodiment of the present invention, the said pharmaceutical composition containing the horse chestnut extract may be administered alone to prevent or treat peri-implantitis.
According to another exemplary embodiment of the present invention, the said pharmaceutical composition containing the horse chestnut extract may be administered in combination with a known drug to treat peri-implantitis. Particularly, the said pharmaceutical composition containing the horse chestnut extract may be administered sequentially or simultaneously with another drug. If being sequentially administered, such composition may be administered before administration of another known drug or after administration of another known drug.
According to another exemplary embodiment of the present invention, the said pharmaceutical composition containing the horse chestnut extract may be used in combination with a known surgical procedure or operation for treating peri-implantitis. Particularly, the said pharmaceutical composition containing the horse chestnut extract may be administered before the surgical procedure or operation, administered along with the surgical procedure or operation, or administered after the surgical operation or treatment.
The said pharmaceutical composition containing the horse chestnut extract according to the present invention may prevent or treat peri-implantitis by being administered into an individual. As used herein, the "individual" means a mammal such as a horse, sheep, pig, goat, dog, etc., including a human, particularly means the human, who has peri-implantitis and whose peri-implantitis may be prevented or treated by administering the said pharmaceutical composition containing the horse chestnut extract according to the present invention thereinto.
The said pharmaceutical composition containing the horse chestnut extract according to the present invention may be administered by a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount enough to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and a level of effective dosage may be determined according to factors including a patient's weight, gender, age, health condition, severity, activity of a drug, sensitivity to a drug, an administration time, an administration route and excretion rate, a treatment period and a concurrently used drug, as well as other factors well known in a medical field.
According to the exemplary embodiments of the present invention, a daily dosage of the said horse chestnut extract may amount to about 0.05 mg/kg to 200 mg/kg, particularly about 0.1 mg/kg to 100 mg/kg, and the said dosage may be appropriately adjusted depending on a patient's age, weight and degree of disease.
According to the exemplary embodiments of the present invention, a content of the said horse chestnut extract per unit dosage form may amount to about 1 mg to 2 g, particularly about 5 mg to 1 g, more particularly about 10 mg to 1 g, and even more particularly about 100 mg to 800 mg.
According to the exemplary embodiments of the present invention, the said horse chestnut extract may be administered once a day or several times a day, particularly twice a day to three times a day, which may be appropriately adjusted depending on a patient's age, weight and degree of disease.
The present invention provides a food composition for preventing or reducing peri-implantitis, containing the horse chestnut extract as an effective component.
The present invention provides the food composition for preventing or reducing peri-implantitis, containing the horse chestnut extract as an effective component, in which the horse chestnut extract contains quercitrin and afzelin.
In the present specification, the said "food composition" means a food prepared and processed by using a raw material or component, which has a functionality useful to the human body.
According to the exemplary embodiments of the present invention, the said horse chestnut extract contained in the said food composition containing the said horse chestnut extract may contain the said quercitrin and the said afzelin at a weight ratio of about 2:1 to 30:1. Particularly, the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 2:1 to 20:1. Also, the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 3:1 to 10:1. More particularly, the horse chestnut extract according to the present invention may contain the said quercitrin and the said afzelin at a weight ratio of about 3:1 to 6:1.
In the said food composition, the matters mentioned in the foregoing pharmaceutical composition may be equally applied to the said horse chestnut extract, if not contradictory to each other.
In the present invention, the said food composition may be also taken in as it is or along with another food or food component, and may be appropriately taken in according to a conventional method.
A type of the said food composition is not particularly limited. As examples of the said food composition containing the horse chestnut extract as an effective component, there are a variety of soups, beverages, teas, health drinks, alcoholic beverages, vitamin complexes and the like, and all the health foods in a conventional sense may be included.
The composition containing the horse chestnut extract according to the present invention may contain various nutritional supplements, vitamin, electrolyte, flavoring agent, coloring agent, pectic acid and salts thereof, alginic acid and salts thereof, organic acid, protective colloidal thickener, pH adjusting agent, stabilizer, preservative, glycerin, alcohol, carbonator used in carbonated beverage, etc. Besides, the food composition according to the present invention may contain natural fruit juice and pulp for preparing fruit juice beverage and vegetable based beverage. Such components may be used independently or in combination.
The present invention provides a method for preparing a horse chestnut extract, including: a first step of crushing a horse chestnut; and a second step of putting the crushed horse chestnut into an alcohol aqueous solution and performing an extraction therefrom.
According to the exemplary embodiments of the present invention, the said alcohol may be an alcohol having 1 to 4 carbon atoms, particularly methanol, ethanol or a mixture thereof, and more particularly ethanol.
According to the exemplary embodiments of the present invention, the extraction in the said second step may be performed at about 40℃ to 90℃, particularly at about 45℃ to 85℃.
According to the exemplary embodiments of the present invention, the extraction in the said second step may be a known extraction method, for example, an ultrasonic extraction method or a reflux extraction method, but is not limited thereto.
According to the exemplary embodiments of the present invention, the said method may further include a step of drying the horse chestnut, before crushing the said horse chestnut.
According to the exemplary embodiments of the present invention, the said method may further include a third step of filtering and concentrating an extract obtained in the said second step.
According to the exemplary embodiments of the present invention, the said method may further include a fourth step of drying a concentrate obtained in the third step and preparing a resulting dry product into powder.
According to the exemplary embodiments of the present invention, the said method may further include a step of performing a supercritical treatment for a crushed horse chestnut between the said first step and the said second step.
The said supercritical treatment may use carbon dioxide as fluid, in which a treatment temperature, pressure and treatment time may be appropriately adjusted by those skilled in the art.
According to the present invention, the said horse chestnut extract contains quercitrin and afzelin.
According to the exemplary embodiments of the present invention, the said horse chestnut extract may contain the said quercitrin in an amount of about 0.5 wt% to 7 wt%, based on the total weight of the horse chestnut extract.
According to the exemplary embodiments of the present invention, the said horse chestnut extract may contain the said afzelin in an amount of about 0.02 wt% to 2.5 wt%, particularly in an amount of about 0.1 wt% to 1.5 wt%, based on the total weight of the horse chestnut extract.
The present invention may provide a pharmaceutical composition containing the horse chestnut extract prepared by means of the said preparation method as an effective component. The said pharmaceutical composition may be the same as described in the pharmaceutical composition described above.
The present invention may provide a food composition containing the horse chestnut extract prepared by means of the said preparation method as an effective component. The said food composition may be the same as described in the food composition described above.
The present invention provides a method for preventing or treating peri-implantitis by administering the pharmaceutical composition containing the horse chestnut extract into an individual. According to the said method, the said horse chestnut extract contains quercitrin and afzelin.
The present invention provides a use of the horse chestnut extract for preventing or treating peri-implantitis. In the said use, the said horse chestnut extract contains quercitrin and afzelin.
The present invention provides a use of the horse chestnut extract for preparing a drug, which is used to prevent or treat peri-implantitis. In the said use, the said horse chestnut extract contains quercitrin and afzelin.
Matters mentioned in the pharmaceutical composition according to the present invention may be also equally applied to a method for manufacturing an extract, a food composition, a treatment method and a use, if not contradictory to each other.
A pharmaceutical composition containing a horse chestnut extract according to the present invention as an effective component has an effect of preventing or treating peri-implantitis.
FIG. 1 graphically illustrates an effect of a horse chestnut extract on inhibiting VEGF.
FIG. 2 graphically illustrates a result of NO production. In the said FIG. 2, a vertical axis shows an absorbance.
FIG. 3 graphically illustrates a result of a cytotoxicity assay experiment.
FIG. 4 graphically illustrates an expression level of intereukin-6 measured by means of an ELISA.
FIG. 5 graphically illustrates an expression level of cyclooxygenase measured by means of an ELISA.
FIG. 6 graphically illustrates an expression level of prostaglandin measured by means of an ELISA.
FIG. 7 graphically illustrates an HPLC result of the horse chestnut extract.
FIG. 8 graphically illustrates an HPLC result of quercitrin and afzelin reference standards.
Hereinafter, the present invention will be described in detail through Examples for better understanding of the present invention. However, the following Examples are provided only for the purpose of illustrating the present invention, and thus the scope of the present invention is not limited thereto. The Examples of the present invention are provided to more completely describe the present invention to those having ordinary skill in the art.
Preparation Example 1. Preparation of a horse chestnut extract
The leaves of a horse chestnut (
Aesculus hippocastanum L.), collected at Doma-dong and Jeonmin-dong, Daejeon Metropolitan City, South Korea, were dried at room temperature in the shade, and then crushed. An extraction from about 30 g of resulting crushed leaves was performed by means of about 600 ml of about 25% (w/v) ethanol at about 80℃ for two hours, and a resulting extract was filtered. A resulting filtrate was concentrated, and thus a resulting extract of the horse chestnut leaves was obtained by about 3.4 g. Hereinafter, the horse chestnut extract prepared in Example 1 was designated as ALH-L1005.
Example 1. Identification of inhibitory effect on VEGF
A 96-well plate (Corning, USA) was inoculated with a HUVEC (Human Umbilical Vein Endothelial Cells) at a ratio of 3 x 10
4 cells/well, in which a medium was an EBM-2 + 2% FBS medium. In about 24 hours later, serum free media were treated with VEGF or VEGF + the horse chestnut extract (ALH-L1005) (concentrations of the horse chestnut extract: 6.25, 12.5, 25, 50, 100 ug/ml), then cultured for about 48 hours, then treated with about 50 ul of an XTT reagent per well, then reacted for four hours, and then an observance was measured at about 490 nm by means of an ELISA (enzyme linked immunosorbent assay) reader (Molecular Devices, USA).
The results of the measurement above are shown in a following FIG. 1.
As identified in FIG. 1, it can be seen that a proliferation of the HUVEC was remarkably inhibited in a group treated with the said horse chestnut extract according to the present invention, in comparison with a group not treated with the horse chestnut extract. Accordingly, it can be seen that the horse chestnut extract inhibited the VEGF.
Thus, it can be seen that the horse chestnut extract according to the present invention may effectively treat peri-implantitis by effectively inhibiting the VEGF.
Example 2. Identification of inhibitory effect on inflammatory response
A macrophage in an inflammatory response produces a pro-inflammatory cytokine like an inflammation mediator such as TNF-α, intereukin-6 (IL-6) and IL-1*?*, then synthesizes an inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and then produces NO and prostaglandin E2 (PGE2). Such pro-inflammatory cytokine induces an inflammatory response, and also may cause an inflammatory disease, if a host's immune response is not appropriate.
Thus, an anti-inflammatory effect may be identified by identifying that NO produced from the inflammatory response is inhibited and production of the pro-inflammatory cytokine is inhibited.
Example 2-1. Inhibition of NO production
A concentration of nitric oxide (NO) in a culture fluid was measured by means of a Griess response. RAW 264.7 cells were adjusted at a ratio of 1 x 10
6 cells/mL, then inoculated into a 24-well plate, and then pre-cultured in a about 5% CO
2 incubator at about 37℃ for two hours. After that, the cells were treated with the horse chestnut extract obtained in Example 1 at ratios of 0, 25, 50, 75 and 100 ug/mL, then stimulated by means of an LPS of 1 ug/mL in one hour later, and then mainly cultured for about 24 hours. A resulting supernatant and a Griess reagent (1% sulfanilamide + 0.1% naphthylendiamine dihydrochloride, 1:1) were reacted to each other at a ratio of 1:1 at room temperature for about 10 minutes, and then an observance thereof was measured at about 540 nm by means of a microplate reader.
The results of the measurement above are shown in following Table 1 and FIG. 2. In the following Table 1, an absorbance of a control group without any treatment and that of a group treated with both the LPS and the horse chestnut extract were indicated as % based on an observance (100%) of a group treated with the LPS only.
From the results of Table 1 and FIG. 2 above, it may be identified that the horse chestnut extract according to the present invention inhibited an NO production at concentrations of 25, 50, 75 and 100 ug/mL.
Example 2-2. Cytotoxicity assay test
A murine macrophage cell line, i.e. RAW264.7 cells were divided into a 96-well plate (Corning, USA) so that the number of cells may amount to 1 x 10
4 cells/well, and then cultured in a CO
2 incubator (37℃, 5% CO
2) for two hours. After cultivation, the resulting cells were treated with the horse chestnut extract according to the present invention at each concentration of 0, 25, 50, 75 and 100 ug/mL, and cultured at about 37℃ for one hour. After cultivation, the resulting cells were treated with lipopolysaccharides (LPS) at a concentration of 1 ug/mL, and cultured at about 37℃ for about 24 hours. After that, the resulting cells were treated with an XTT reagent at a ratio of about 50 ul per well, then reacted for four hours, then an observance change thereof was measured at about 490 nm by means of the ELISA reader (Molecular Devices, USA), and then a cell viability thereof was indicated as a percentage.
The results of the measurement above are shown in following Table 2 and FIG. 3.
From the results of the said Table 2 and FIG. 3, it can be seen that the horse chestnut extract according to the present invention had no cytotoxicity at concentrations of 25, 50, 75 and 100 ug/mL, and it may be identified that an inhibitory effect on the NO production in Example 2-1 was not caused by cytotoxicity.
Example 2-3. Inhibition of intereukin-6 expression
An amount of intereukin-6 (IL-6) secretion from RAW 264.7 cells in a cell culture fluid was measured by using an ELISA kit (Mouse ELISA set, R&D Systems Inc.). To obtain the cell culture fluid, the RAW 264.7 cells were adjusted at a ratio of 5 x 10
6 cells/mL, then inoculated into a 24-well plate, then was pre-cultured for two hours, and then treated with the inventive horse chestnut extract at each concentration of 0, 25, 50, 75 and 100 ug/mL as well as an LPS of 1 ug/mL. After that, a main cultivation was performed for about 24 hours, and thus supernatant was obtained through centrifugation. In case of the ELISA, an anti-mouse IL-6 was divided into a microplate as a capture antibody, and then coated overnight at room temperature. After that, the microplate was washed with a wash buffer (#WA126, R&D Systems Inc.), then blocked by means of a reagent diluent (#DY995, R&D Systems Inc.), then washed with the wash buffer, and then a supernatant of cell culture was divided into each microplate well and reacted at room temperature for two hours. After the reaction, the microplate was washed with the wash buffer, and then a diluted biotinylated anti-mouse IL-6 detection antibody and streptavidin-horseradish peroxidase conjugate were divided thereinto and reacted at room temperature for about 20 minutes. After that, the microplate was washed with the wash buffer again, then a substrate solution (#DY999, R&D Systems Inc.) was added thereinto, and then dark-reacted at room temperature for about 20 minutes. The reaction was ended by means of a stop solution (#DY994, R&D Systems Inc.), and then an observance thereof was measured at about 450 nm by means of a microplate reader.
The results of the measurement in the experiment above are shown in following Table 3 and FIG. 4.
From the results of the said Table 3 and FIG. 4, it was identified that the horse chestnut extract according to the present invention reduced an expression level of intereukin-6, i.e. the pro-inflammatory cytokine at concentrations of 25, 50, 75 and 100 ug/mL.
Considering all the experimental results above, it can be seen that the horse chestnut extract according to the present invention inhibited an NO production, had no cytotoxicity, and reduced an expression level of intereukin-6, i.e. the pro-inflammatory cytokine. From the results above, it may be identified that the horse chestnut extract according to the present invention showed an anti-inflammatory action by reducing the NO production with regard to Raw264.7 of macrophage, in which inflammation was induced by means of lipopolysaccharide (LPS), as well as an expression level of interleukin-6, i.e. an intracellular pro-inflammatory cytokine.
Example 2-4. Inhibition of cyclooxygenase (COX-2) in an in-vitro model of peri-implantitis
An amount of cyclooxygenase (COX-2) secretion from MG63 cells in a cell culture fluid was measured by using the ELISA kit (R&D Systems Inc.). To obtain the cell culture fluid, the MG63 cells were adjusted at a ratio of 1 X 10
6 cells/mL, then inoculated into a 60 mm culture plate, then pre-cultured for two hours, and then treated with the inventive horse chestnut extract at each concentration of 0, 25, 50, 75 and 100ug/mL as well as 10 ug/mL of LPS. After that, the medium was discarded after a main culture for 48 hours, then the resulting cells were washed twice with PBS, then proteins were isolated therefrom by using a lysis buffer, and then used for the ELISA. For the ELISA, anti-human/mouse COX-2 was divided into a microplate as a capture antibody and then coated overnight at room temperature. After that, the microplate was washed with a wash buffer, then blocked by means of a block buffer, then washed again with the wash buffer, after which isolated cell proteins were divided into each microplate well, and then subjected to reaction at room temperature for two hours. After the reaction, the microplate was washed with the wash buffer, after which diluted biotinylated anti-human/mouse COX-2 detection antibody and streptavidin-horseradish peroxidase conjugate were divided thereinto, and then subjected to reaction at room temperature for 20 minutes. After that, the microplate was washed with the wash buffer, after which a substrate solution was added thereinto, and then subjected to a dark reaction at room temperature for 20 minutes. The reaction was ended by mean of a stop solution, and then an absorbance thereof was measured at 450 nm by means of a microplate reader.
The results of the measurement above are shown in following Table 4 and FIG. 5.
Considering the experimental results above, it might be seen that the horse chestnut extract according to the present invention decreases an expression level of cyclooxygenase (COX-2) in a cell experiment using MG63, i.e. an in vitro model of peri-implantitis. From the results above, it might be identified that the horse chestnut extract according to the present invention achieves an effect on peri-implantitis by decreasing the expression level of cyclooxygenase (COX-2) with regard to MG63, in which an inflammation is induced by means of lipopolysaccharide (LPS), and thus showing an anti-inflammatory action.
Example 2-5. Inhibition of prostaglandin (PGE2) in the in vitro model of peri-implantitis
An amount of prostaglandin (PGE2) secretion from MG63 cells in a cell culture fluid was measured by using the ELISA kit (R&D Systems Inc.). To obtain the cell culture fluid, the MG63 cells were adjusted at a ratio of 1 X 10
6 cells/mL, then inoculated into a 60 mm culture plate, then pre-cultured for two hours, and then treated with the inventive horse chestnut extract at each concentration of 0, 25, 50, 75 and 100 ug/mL as well as 10 ug/mL of LPS. For the ELISA, the cell culture fluid and a primary antibody solution (anti-PGE2 mouse monoclonal antibody) were inserted into a microplate, then subjected to reaction at room temperature for one hour, after which PGE2 conjugate was added thereinto, and then further subjected to reaction (for competitive ELISA) for two hours. After that, the microplate was washed four times in total with the wash buffer, after which the substrate solution was added thereinto, and then subjected to the dark reaction at room temperature for 30 minutes. The reaction was ended by mean of the stop solution, and then an absorbance thereof was measured at 450 nm by means of the microplate reader.
The results of the measurement above are shown in following Table 5 and FIG. 6.
Considering the experimental results above, it might be seen that the horse chestnut extract according to the present invention inhibits a production of prostaglandin (PGE2), i.e. an inflammation mediator in a cell experiment using MG63, i.e. an in vitro model of peri-implantitis. From the results above, it might be identified that the horse chestnut extract according to the present invention achieves an effect on peri-implantitis by inhibiting the production of prostaglandin (PGE2), i.e. a pro-inflammatory cytokine with regard to MG63, in which an inflammation is induced by means of lipopolysaccharide (LPS), and thus showing an anti-inflammatory action.
Experimental Example 1. Quercitrin, afzelin and contents (%) thereof in the horse chestnut extract
Whether or not ALH-L1005, i.e. the horse chestnut extract, contains quercitrin and afzelin was identified as follows.
100 mg of ALH-L1005 was inserted into a tube, then fully dissolved in about 100 ml of 100% MeOH, then filtered through a 0.22 μm filter, and then HPLC was performed. The results thereof are as shown in FIG. 7.
Also, the HPLC was equally performed for a quercitrin reference standard (Sigma-Aldrich) and an afzelin reference standard (Sigma-Aldrich). The results thereof are as shown in FIG. 8.
The conditions for performing the HPLC are as follows:
i) Column: CAPCELL PAK C18 UG120 (SHISEIDO, 4.6 x 250 mm, 5 μm)
ii) Detector: UV 254 nm
iii) Flow rate: 1.0 ml/min
iv) Mobile phase
Mobile phase A: 0.1% (w/v) Formic acid\Mobile phase B: Acetonitrile
v) Injection volume: 10 μL
From FIGS. 7 and 8, it was identified that the horse chestnut extract of Preparation Example 1 contained quercitrin and afzelin. Particularly, the quercitrin reference standard in the said FIG. 2 showed a peak at a position where a retention time (RT) value is about 15 minutes, while the afzelin reference standard showed a peak at a position where the RT value is about 18 minutes. Meanwhile, the horse chestnut extract of the said FIG. 1 also showed a peak at the same RT value, and thus it was clearly identified that ALH-L1005, i.e. the horse chestnut extract, contained quercitrin and afzelin.
Also, a weight ratio of quercitrin and afzelin to ALH-L1005, which was measured from the HPLC above, corresponded to about 4:1 to 5:1. The said horse chestnut extract contained quercitrin in an amount of about 1.88 to 2.20 wt% based on the total weight of the horse chestnut, and contained afzelin in an amount of about 0.41 to 0.5 wt% based on the total weight of the horse chestnut.
Claims (9)
- A pharmaceutical composition for preventing or treating peri-implantitis, comprising a horse chestnut extract as an effective component.
- The pharmaceutical composition for preventing or treating peri-implantitis, according to claim 1, wherein the said horse chestnut extract comprises quercitrin and afzelin.
- The pharmaceutical composition for preventing or treating peri-implantitis, according to claim 2, wherein the said horse chestnut extract comprises the said quercitrin and the said afzelin at a weight ratio of 2:1 to 30:1.
- The pharmaceutical composition for preventing or treating peri-implantitis, according to claim 1 or 2, wherein the said horse chestnut extract is an alcohol aqueous solution extract.
- The pharmaceutical composition for preventing or treating peri-implantitis, according to claim 1 or 2, wherein a content of the said horse chestnut extract amounts to 0.005 wt% to 70 wt% based on the total weight of the said composition.
- A method for preparing a horse chestnut extract containing afzelin and quercitrin, wherein the method comprises:a first step of crushing a horse chestnut; anda second step of putting the crushed horse chestnut into an alcohol aqueous solution and performing an extraction therefrom.
- A food composition for preventing or reducing peri-implantitis, comprising a horse chestnut extract as an effective component.
- The food composition for preventing or reducing peri-implantitis, according to claim 7, wherein the said horse chestnut extract comprises quercitrin and afzelin.
- The food composition for preventing or reducing peri-implantitis, according to claim 8, wherein the said horse chestnut extract comprises the said quercitrin and the said afzelin at a weight ratio of 2:1 to 30:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020207019980A KR20200091925A (en) | 2017-12-22 | 2018-12-21 | Composition comprising a horse chestnut extract |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0178256 | 2017-12-22 | ||
| KR20170178256 | 2017-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019125058A1 true WO2019125058A1 (en) | 2019-06-27 |
Family
ID=66993654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2018/016486 WO2019125058A1 (en) | 2017-12-22 | 2018-12-21 | Composition comprising a horse chestnut extract |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20200091925A (en) |
| WO (1) | WO2019125058A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114105929A (en) * | 2021-10-11 | 2022-03-01 | 河南大学 | Method for preparing kaempferol and afzerin from Chinese redbud leaf extract |
| WO2023033535A1 (en) * | 2021-09-01 | 2023-03-09 | Angiolab, Inc. | Composition comprising horse chestnut extract |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100533777B1 (en) * | 2001-10-26 | 2005-12-06 | 주식회사 안지오랩 | Composition for inhibiting angiogenesis containing an extract of horse chestnut |
| US20060030697A1 (en) * | 2002-03-25 | 2006-02-09 | Council Of Scientific & Industrial Research | Simple process for obtaining beta-aescin from indian horse chesnut (aesculus indica) |
| KR100882265B1 (en) * | 2007-01-29 | 2009-02-09 | 주식회사 안지오랩 | Method for producing extract of horse chestnut leaf |
| JP2014024771A (en) * | 2012-07-25 | 2014-02-06 | Kanpo Shika Igaku Kenkyusho:Kk | Composition for preventing and treating periodontal disease and preservative for cosmetic |
| KR20180001047A (en) * | 2016-06-24 | 2018-01-04 | 주식회사 안지오랩 | Composition of an extract of horse chestnut |
-
2018
- 2018-12-21 KR KR1020207019980A patent/KR20200091925A/en not_active Application Discontinuation
- 2018-12-21 WO PCT/KR2018/016486 patent/WO2019125058A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100533777B1 (en) * | 2001-10-26 | 2005-12-06 | 주식회사 안지오랩 | Composition for inhibiting angiogenesis containing an extract of horse chestnut |
| US20060030697A1 (en) * | 2002-03-25 | 2006-02-09 | Council Of Scientific & Industrial Research | Simple process for obtaining beta-aescin from indian horse chesnut (aesculus indica) |
| KR100882265B1 (en) * | 2007-01-29 | 2009-02-09 | 주식회사 안지오랩 | Method for producing extract of horse chestnut leaf |
| JP2014024771A (en) * | 2012-07-25 | 2014-02-06 | Kanpo Shika Igaku Kenkyusho:Kk | Composition for preventing and treating periodontal disease and preservative for cosmetic |
| KR20180001047A (en) * | 2016-06-24 | 2018-01-04 | 주식회사 안지오랩 | Composition of an extract of horse chestnut |
Non-Patent Citations (1)
| Title |
|---|
| KIM, SE EUN ET AL.: "Efficacy of horse chestnut leaf extract ALH-L1005 as a matrix metalloproteinase inhibitor in ligature-induced periodontitis in canine model", JOURNAL OF VETERINARY SCIENCE, vol. 18, no. 2, 22 June 2017 (2017-06-22), pages 245 - 251, XP055620951 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023033535A1 (en) * | 2021-09-01 | 2023-03-09 | Angiolab, Inc. | Composition comprising horse chestnut extract |
| CN114105929A (en) * | 2021-10-11 | 2022-03-01 | 河南大学 | Method for preparing kaempferol and afzerin from Chinese redbud leaf extract |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200091925A (en) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018194309A1 (en) | Pharmaceutical composition containing indirubin derivative as active ingredient | |
| WO2018117659A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
| WO2019125058A1 (en) | Composition comprising a horse chestnut extract | |
| US20060121132A1 (en) | TNF-alpha production inhibitor comprising kavalactone as an active ingredient | |
| WO2010036052A2 (en) | Composition containing 4-o-methylhonokiol for treating or preventing amyloid- related diseases | |
| WO2018225882A1 (en) | Pharmaceutical composition for improvement of erectile function and for prevention and treatment of prostatic hyperplasia in male menopausal symptoms, comprising extracts of lespedeza cuneata and fenugreek | |
| WO2012008788A2 (en) | Composition containing serine as an active ingredient for the prevention and treatment of fatty liver diseases, and use thereof | |
| WO2021230581A1 (en) | Discovery of novel akkermansia muciniphila ak32 and application thereof for prevention or treatment of intestinal injury | |
| WO2016186349A2 (en) | Composition, containing quisaqualis indica extract, for preventing or treating prostatic hyperplasia | |
| WO2013122345A1 (en) | Improved dosage form containing extract from bark of liriodendron tulipifera as active ingredient | |
| US20150011623A1 (en) | Pharmaceutical Composition Containing as Active Ingredient Extract From Bark of Liriodendron Tulipifera | |
| WO2019031655A1 (en) | Composition comprising thymol as effective ingredient for preventing or treating skin wrinkle or atopic dermatitis | |
| WO2021080298A1 (en) | Composition containing enteroccocus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby | |
| WO2012138076A2 (en) | Composition containing herbal extract mixture for prevention or treatment of gastrointestinal diseases | |
| WO2020055015A1 (en) | Pharmaceutical composition for preventing or treating non-alcoholic steatohepatitis, containing, as active ingredient, tazemetostat or derivative thereof | |
| WO2020235952A1 (en) | Pharmaceutical composition comprising a fraction of melissa officinalis leaf extract | |
| WO2022080523A1 (en) | Composition comprising a mixture of medicinal herbal extracts from indigo pulverata levis, broussonetia kazinoki, and juglans mandshurica for preventing or treating inflammatory bowel disease | |
| WO2022031092A1 (en) | Composition for prevention, amelioration, or treatment of inflammatory diseases or immune diseases comprising gancaonin n as active ingredient | |
| WO2011102695A9 (en) | Composition for preventing or treating diseases caused by over-expression of lxrα, containing liquiritigenin or isoliquiritigenin as active ingredient | |
| WO2022102801A1 (en) | Composition for improving cognitive ability and preventing and treating dementia and hyperactivity disorder, containing galla rhois extract and ampicillin as active ingredients | |
| WO2021256865A1 (en) | Pharmaceutical composition containing saururus chinensis fraction, and preparation method therefor | |
| WO2015083996A1 (en) | Pharmaceutical dosage form for treating chronic myeloid leukemia, containing liriodendron tulipifera l. bark extract as active ingredient | |
| WO2016056769A1 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containing, as active ingredient, cerulenin or cerulenin derivative | |
| WO2021033994A1 (en) | Composition comprising salvia miltiorrhiza or paeonia lactiflora extract as active ingredient for prevention or treatment of lipid metabolism disorder | |
| WO2023277461A1 (en) | Pharmaceutical composition for preventing or treating neurodegenerative diseases comprising 20(s)-ginsenoside rg3 as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18892027 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 20207019980 Country of ref document: KR Kind code of ref document: A |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18892027 Country of ref document: EP Kind code of ref document: A1 |